General Information

Age Group

Adults

Status

Recruiting

Protocol Number

NCT06115499

Background Information

This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.

 

For more information, please visit https://clinicaltrials.gov/study/NCT06115499.

Offered At

Inova Schar Cancer
8081 Innovation Park Drive
Fairfax, VA 22031
Principal Investigator

Raymond Wadlow, MD

Eligibility Information

  • Metastatic pancreatic adenocarcinoma. Adenosquamous carcinoma, squamous carcinoma, acinar cell carcinoma, and carcinoma not otherwise specified are also acceptable
  • BRCA1/2 or PALB2 mutation (somatic or germline) identified on any Clinical Laboratory Improvement Amendments (CLIA)-certified gene panel. Mutations must be considered pathogenic or likely pathogenic by a reference database such as ClinVar or OncoKb.org. (Submission of mutation report will be required)
  • Measurable disease
  • Potential trial participants should have recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment
  • Clinical or radiographic progression on first-line FOLFIRINOX (or nanoliposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin [NALIRIFOX]) for metastatic disease
  • Age greater than or equal to 18 years